News

Sandoz, a Novartis division and a global leader in biosimilars, announced the first patient enrolled in ROSALIA, an integrated Phase I/III clinical study for its proposed biosimilar…
Read More...

ACADIA Pharmaceuticals Inc. announced top-line results from its Phase 3 ENHANCE study, which evaluated pimavanserin as an adjunctive treatment in adult schizophrenia patients with…
Read More...

Vertex Pharmaceuticals Incorporated announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the VX-445 (elexacaftor), tezacaftor and…
Read More...

Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral…
Read More...

Celltrion and Nan Fung Group announced the establishment of Vcell Healthcare Limited, a Joint Venture company between both parties. At the formation of the Joint Venture, Vcell…
Read More...

Aridis Pharmaceuticals, Inc. announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to AR-501, the Company's inhaled formulation of gallium citrate for…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of an extension application to the European Medicines Agency (EMA) for subcutaneous (under the…
Read More...

MilliporeSigma and the Broad Institute of MIT and Harvard announced an agreement to offer non-exclusive licenses to CRISPR intellectual property (IP) under their respective control for…
Read More...

Mallinckrodt plc and Silence Therapeutics plc announced a collaboration that will allow the companies to develop and commercialize RNAi drug targets designed to inhibit or 'silence' the…
Read More...

"It is exciting news for MS patients in China that Gilenya has received fast approval. The approval of Gilenya and the upcoming regulatory review for Mayzent demonstrate our commitment…
Read More...

Results from the INMARK study, a randomised, double-blind clinical trial of Ofev (nintedanib) vs. placebo (12 weeks) followed by an open label period (40 weeks) in patients with…
Read More...

Astellas Pharma Inc. and Frequency Therapeutics, Inc. announced that they have entered into an exclusive license agreement to develop and commercialize Frequency’s regenerative…
Read More...

TraceLink Inc. announced a partnership with Excellis Health Solutions to provide local implementation services for TraceLink's Russia compliance solution, helping pharmaceutical…
Read More...

Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of cancer, and AUM Biosciences (AUM), a company focused on the development of…
Read More...

Amgen and Allergan plc announced that MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab), and KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin (trastuzumab), are…
Read More...

Quotient Sciences and global investment firm Permira announced that a company backed by the Permira Funds has signed a definitive agreement to acquire a majority stake in Quotient from…
Read More...

The U.S. Food and Drug Administration has approved Recarbrio (imipenem, cilastatin and relebactam), an antibacterial drug product to treat adults with complicated urinary tract…
Read More...

Lonza has selected Rockwell Automation for the turnkey implementation of the Lonza strategic vision of bringing the digital factory to nine former Capsugel facilities that manufacture…
Read More...

Epistem Limited, the UK based pre-clinical and clinical research services company announces the expansion of its in vitro model portfolio by the completion of an agreement with Hubrecht…
Read More...

Novartis announced the US Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) and has granted Priority Review for its investigational sickle…
Read More...